A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder

Completed · Phase 4 · Has a placebo group

Conditions studied: Anxiety Disorders,Generalized Anxiety Disorder

In brief

This is a study in minors (7 to 17 years old) diagnosed with generalized anxiety disorder (GAD) and evaluated using standard questionnaires as having at least moderate severity of GAD. Participating minors will be assigned to receive either the study drug escitalopram or a pill without any drug in it called a placebo. The purpose of this research is to study the safety and effectiveness of escitalopram in minors with GAD.

Key facts

Study ID

NCT03924323

Run by

AbbVie

People needed

273

Starts

2019-05-30

Expected to finish

2021-09-20

Last updated by the study team

2022-11-14

Who can join

Age: 7 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject's parent/legal representative must give written informed consent, including privacy authorization, prior to study participation. The subject will complete an informed assent prior to study participation.
• Subject meets DSM-5 criteria for a primary diagnosis of GAD at screening established by a comprehensive psychiatric evaluation and confirmed/supported using the Mini-International Neuropsychiatric Interview for children and adolescents (MINI Kid).
• Male subjects who are sexually active with a partner of childbearing potential must use, with their partner, a condom plus an approved method of highly effective contraception from the time of informed consent until 14 days after the last dose of study drug.
• Female subjects who are sexually active and are of childbearing potential must use, with their partner, an approved method of highly effective contraception from the time of informed consent until 14 days after the last dose of study drug.
• Female subjects who are not of childbearing potential do not need to use any methods of contraception. This includes preadolescent and adolescent females who have not reached menarche. - Subject must have venous access enough to allow blood sampling and be compliant with blood draws as per the protocol.

You may not qualify if…

• Current diagnosis of MDD, attention-deficit/hyperactivity disorder, or lifetime diagnosis of bipolar disorder, psychotic depression, schizophrenia or other psychotic disorder, feeding and/or eating disorder, obsessive-compulsive disorder, conduct disorder, oppositional defiant disorder, post-traumatic stress disorder, panic disorder, or pervasive development disorder.
• Suspected or previously diagnosed intellectual disability disorder.
• One or more first-degree relatives with diagnosed bipolar I disorder.
• History of seizure disorder (other than febrile seizures).
• History of electroconvulsive therapy at any time during the subject's lifetime.
• Known hypersensitivity to escitalopram (escitalopram oxalate) or citalopram or any of the inactive ingredients or had frequent or severe allergic reactions to multiple medications.
• Taking any medications that are contraindicated to escitalopram (escitalopram oxalate).
• Inability to speak, read, or understand English well enough to complete the assessments.
• No active suicidal ideation or lifetime history of suicidal behavior as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS).

Where it is running

• Harmonex /ID# 233342 — Dothan, Alabama, United States
• Woodland International Research Group /ID# 233348 — Little Rock, Arkansas, United States
• Woodland Research Northwest, LLC /ID# 233366 — Rogers, Arkansas, United States
• ATP Clinical Research, Inc /ID# 233362 — Costa Mesa, California, United States
• ProScience Research Group /ID# 233374 — Culver City, California, United States
• Sun Valley Research Center /ID# 233343 — Imperial, California, United States
• MCB Clinical Research Centers /ID# 233372 — Colorado Springs, Colorado, United States
• Emerson Clinical Research Inst /ID# 233371 — Washington D.C., District of Columbia, United States
• Innovative Clinical Research /ID# 233365 — Fort Lauderdale, Florida, United States
• Indago Research and Health Cen /ID# 233364 — Hialeah, Florida, United States
• CNS Healthcare - Jacksonville /ID# 233352 — Jacksonville, Florida, United States
• Accel Research Sites-Maitland Clinical Research Unit /ID# 233368 — Maitland, Florida, United States
• Medical Research Group of Central Florida /ID# 233357 — Orange City, Florida, United States
• Clinical Neuroscience Solutions, Inc /ID# 233350 — Orlando, Florida, United States
• APG Research, LLC /ID# 233337 — Orlando, Florida, United States
• University of South Florida Rothman Center of Neuropsychiatry /ID# 233356 — St. Petersburg, Florida, United States
• Capstone Clinical Research /ID# 233354 — Libertyville, Illinois, United States
• Baber Research Group /ID# 233363 — Naperville, Illinois, United States
• Psychiatric Associates /ID# 233360 — Overland Park, Kansas, United States
• Alivation Research /ID# 233338 — Lincoln, Nebraska, United States
• Center for Psychiatry and Behavioral Medicine Inc /ID# 233355 — Las Vegas, Nevada, United States
• Manhattan Behavioral Medicine PLLC /ID# 233351 — New York, New York, United States
• Finger Lakes Clinical Research /ID# 233347 — Rochester, New York, United States
• Quest Therapeutics of Avon Lake /ID# 233367 — Avon Lake, Ohio, United States
• Neuro-Behavioral Clinical Research, Inc. /ID# 233375 — Canton, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.